AT Bancorp increased its stake in shares of Alexion Pharmaceuticals (NASDAQ:ALXN) by 5.8% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 14,449 shares of the biopharmaceutical company’s stock after acquiring an additional 792 shares during the period. AT Bancorp’s holdings in Alexion Pharmaceuticals were worth $1,611,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors also recently modified their holdings of the company. TIAA CREF Investment Management LLC grew its holdings in Alexion Pharmaceuticals by 12.1% in the 4th quarter. TIAA CREF Investment Management LLC now owns 3,836,919 shares of the biopharmaceutical company’s stock valued at $458,857,000 after buying an additional 414,969 shares during the last quarter. Clearbridge Investments LLC grew its holdings in Alexion Pharmaceuticals by 9.5% in the 4th quarter. Clearbridge Investments LLC now owns 3,541,871 shares of the biopharmaceutical company’s stock valued at $423,572,000 after buying an additional 307,117 shares during the last quarter. Franklin Resources Inc. grew its holdings in Alexion Pharmaceuticals by 10.4% in the 4th quarter. Franklin Resources Inc. now owns 2,583,710 shares of the biopharmaceutical company’s stock valued at $308,986,000 after buying an additional 243,650 shares during the last quarter. Geode Capital Management LLC grew its holdings in Alexion Pharmaceuticals by 2.8% in the 4th quarter. Geode Capital Management LLC now owns 2,256,415 shares of the biopharmaceutical company’s stock valued at $269,251,000 after buying an additional 62,266 shares during the last quarter. Finally, UBS Asset Management Americas Inc. grew its holdings in Alexion Pharmaceuticals by 10.3% in the 4th quarter. UBS Asset Management Americas Inc. now owns 1,871,548 shares of the biopharmaceutical company’s stock valued at $223,818,000 after buying an additional 174,606 shares during the last quarter. 95.67% of the stock is currently owned by institutional investors and hedge funds.
A number of analysts have commented on the company. Stifel Nicolaus raised their price objective on Alexion Pharmaceuticals from $151.00 to $155.00 and gave the stock a “buy” rating in a research report on Friday, April 27th. Evercore ISI upgraded Alexion Pharmaceuticals from an “in-line” rating to an “outperform” rating in a research report on Monday, February 5th. Zacks Investment Research upgraded Alexion Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, April 10th. Nomura raised their target price on Alexion Pharmaceuticals from $148.00 to $156.00 and gave the stock a “buy” rating in a research report on Thursday, March 15th. Finally, Robert W. Baird set a $160.00 target price on Alexion Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, March 15th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and twenty have given a buy rating to the company’s stock. Alexion Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $155.50.
In other news, EVP Julie O’neill sold 1,625 shares of Alexion Pharmaceuticals stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $119.83, for a total value of $194,723.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Christopher J. Coughlin bought 10,000 shares of the stock in a transaction dated Monday, April 30th. The stock was purchased at an average cost of $120.79 per share, with a total value of $1,207,900.00. Following the completion of the purchase, the director now directly owns 26,333 shares in the company, valued at approximately $3,180,763.07. The disclosure for this purchase can be found here. Insiders own 4.35% of the company’s stock.
Shares of Alexion Pharmaceuticals opened at $121.15 on Friday, according to MarketBeat.com. The company has a quick ratio of 2.86, a current ratio of 3.35 and a debt-to-equity ratio of 0.33. Alexion Pharmaceuticals has a 52-week low of $120.20 and a 52-week high of $121.73. The firm has a market capitalization of $27.04 billion, a price-to-earnings ratio of 23.48, a price-to-earnings-growth ratio of 1.10 and a beta of 1.11.
Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings data on Thursday, April 26th. The biopharmaceutical company reported $1.68 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.50 by $0.18. Alexion Pharmaceuticals had a return on equity of 13.70% and a net margin of 14.46%. The firm had revenue of $930.90 million during the quarter, compared to the consensus estimate of $920.50 million. During the same quarter in the previous year, the company posted $1.38 EPS. The business’s revenue for the quarter was up 7.0% compared to the same quarter last year. equities research analysts forecast that Alexion Pharmaceuticals will post 6.28 earnings per share for the current year.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease.
Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals (NASDAQ:ALXN).
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.